Navigation thread
Navigation thread
Unit of Cancer immunotherapy
Cancer immunotherapy can be classified into two main categories: (1) passive (monoclonal antibodies); and (2) active (adoptive cell immunotherapy), using lymphocytes extracted directly from the tumour or from the blood, which may or may not be genetically modified.
The fundamental mission of this Functional Unit is the clinical coordination of adoptive cell immunotherapy against tumours at the Hospital Clínic Barcelona, as well as collaboration projects with other public or private institutions, all coordinated with the Immunotherapy Section of the Immunology Service.
Therefore, the general objectives are as follows:
- To consolidate and strengthen the already available academic and commercial therapy with modified T-lymphocytes (CAR T-cell therapy).
- To collaborate in the development of new CAR T-cell products, other cell immunotherapy options (e.g. TIL and TCR) and bispecific antibodies.
- To strengthen the national cell immunotherapy network.
- To promote studies combining this therapy with other more conventional strategies (e.g. immune checkpoint inhibitors, radiotherapy, etc.).
